0
Basket

There are currently no items in your basket.

Supplements

Turmeric & Curcumin | Benefits, Side Effects & Dosage

What Is Turmeric?


     Ancient writings of the explorer Marco Polo mention this spice as far back as 1290 AD. Its description and benefits have been documented in various writings through history, but during the rule of the British in India, between 1858 to 1947, turmeric became known as a component of curry powder, which was shared across the west.

Turmeric is actually a yellow-gold coloured spice, with its distinct colour supplied by the compound curcumin. It became a topic of investigation regarding its health benefits when it was found that its addition into food helped to preserve the foods freshness and palatability.

Curcumin molecules and derivatives (globally labelled curcuminoids) are generally 2-5% of the spices structure but are a key active ingredient (2).

Some varieties of turmeric can contain up to 9% curcumin, however, alongside these compounds, turmeric also contains essential oils and omega 3 fatty acids, as well as proteins and carbohydrates (1). There are also a variety of plant-based naturally occurring compounds (phytochemicals) which include the water soluble antioxidant, turmerol (3).


 

turmeric curry


What Is Curcumin?


 

Curcuminoid molecules are polyphenols, meaning they are chemically structured with a number of carbolic acid molecules. Depending on their structure, they are labelled curcumin I, II or III; and despite confusion as to whether one analogue is able to be more active than the others, it is universally agreed that curcumin is the most potent component of turmeric (4-5).

In fact, this molecule is said to exhibit benefits in a variety of areas of health and physiology. These benefits vary from being an anti-inflammatory and anti-oxidant agent, to a protective agent of organ health (particularly the liver).

The strong anti-oxidant and anti-inflammatory effects are suggested to assist with various areas of cellular development and chemical signalling in our bodies, alongside modulating levels of key proteins and growth factors.

We will elaborate on these miraculous abilities further…

 

 


Anti-Inflammatory Benefits


 

Amazingly, curcumin has a natural anti-inflammatory potency equal to nonsteroidal anti-inflammatory drugs (NSAIDs) such as phenylbutazone (24), and is more potent than the commonly taken Ibuprofen (25)! It also does not come with the potential side effects which other anti-inflammatory agents have.

Its mechanism of anti-inflammatory action appears to be through various pathways including:

✓ Inhibition of induction of COX-2 (an enzyme responsible for inflammation and pain) (26-27)
Inhibition of LOX-2 (another pro-inflammatory enzyme) (28-30)
Inhibition of cytokines (31-36) and transcription factors (37-41) involved with the inflammatory reaction
Inhibition of nitric oxide synthase (an enzyme which stimulates nitric oxide production which is a signalling molecule involved in inflammation) (42)

Additionally, there is evidence that the anti-inflammatory effect of curcumin is due to its anti-oxidant potency (43-46).


turmeric and curcumin


Anti-Oxidant Benefits


 

It is well established that peroxidation of lipid cell membranes and oxidative damage by free radical molecules to DNA and cellular proteins is associated with various diseases and even the aging process. Curcumin is suggested to have a role in fighting against such oxidative stress.

✓ Health against oxidative damage is modulated through control of the reduction-oxidation reaction (redox status). Simply put, the reduction is the gain of an electron (leading to a decrease in oxidation state by a molecule); whilst oxidation is the opposite, the loss of an electron (increase in oxidation state).

Through a few different means, curcumin has been found to modulate redox status of cells and provide oxidative protection.

For example, curcumin assists to suppress lipid peroxidation and protect our cell membranes (47-51).

✓ Additionally, curcumin increases the expression of glutathione in our cells (52-56), which is one of the body’s main protectors against free radicals by scavenging these radicals and reducing oxidative stress.

✓ Finally, curcumin may also have a further role against oxidation through its ability to bind to iron (57).

It is not a surprise then that curcumin (and turmeric) have been found to have an effect on disease processes characterised by oxidative stress. In fact, water and fat soluble turmeric extracts show as strong an antioxidant effect as both vitamin C and vitamin E (58).


Turmeric & Curcumin | Clinical Benefits


#1 Wound Healing

One of the most prescribed uses in folklore and clinical use of curcumin is for the healing of wounds (60). The antioxidant benefits of this compound it seems can assist rate of healing both in laboratory studies and animal model trials (61-63). The antioxidant effects of curcumin help to inhibit against oxidative damage from free radicals such as hydrogen peroxide to protect skin and collagen cells during healing.

 

#2 Arthritis

Another interesting area of benefit is in the management of arthritis, which has been examined using human trials. For example, one study (64) randomised a group of patients with rheumatoid arthritis to receive either curcumin (1200mg per day) or the non-steroidal anti-inflammatory phenylbutazone (300mg per day) for a period of 2 weeks.

Amazingly, the results of this study found that those provided with curcumin showed the same amount of symptom improvement than the anti-inflammatory group, and had no side effects! These symptom benefits included significant reduction of morning joint stiffness, increased walking time and decrease in joint swelling.

Such benefits are also supported by other arthritis studies both on cartilage cells (65-67) and in animal studies (68).

 

#3 Cancer

One of the most incredible therapeutic benefits of curcumin is in its anti-carcinogenic effects, as both the antioxidant and anti-inflammatory roles of this compound can influence the reactions responsible for malignant cell transformation (69).

For example, a 10% reduction in oral cancer lesion size has been demonstrated with the use of turmeric as a topical agent applied to the tongue (70).

Curcumin also demonstrates anti-cancer benefits through the facilitation of reactions which lead to cancer cell apoptosis (death). This has been seen in various types of cancer including:

Head and neck (71)
Lung (72)
Pancreatic (73)
Ovarian (74)
Breast (75)

Due to this amazing ability, it is no wonder that curcumin is being examined as a possible universal cancer preventative agent!


 

high protein vegan recipe


 

#4 Psoriasis

A fantastic bit of research looked at the use of applying curcumin topically to skin suffering from psoriasis lesions (81). During this experiment, the researchers applied a 1% curcumin alcohol gel firstly to a group of 10 people with psoriasis. 5 of these individuals has 90% resolution of their skin lesions between 2-6 weeks, and the other 5 had 50-85% resolution after 8 weeks!

They then compared the curcumin gel to the standard alcohol gel base. After 1 month the entire curcumin group had improved by between 25% and 75%, whilst the control group had either shown no benefit (33%) or had even worsened (66%)!

 

#5 Other Benefits of Turmeric/Curcumin?

For expediency, I should state for the record that curcumin’s therapeutic benefits far exceed that which can be encapsulated into this article!

Instead, I shall list some of the other areas which curcumin has been shown to demonstrate its anti-oxidant and anti-inflammatory effects.

This would include:

Reduction in induction and severity of acute pancreatitis (76)

Reduction in anti-inflammatory response in irritable bowel disease (77)

Improvement in histological signs of colonic inflammation (colitis) (78)

Protection against gastric ulcers (79)

Reduction in mast cell activation from allergies (80-81)

Inhibition of virus replication in HIV (82)

Increases in serotonin and reduction in depressive behaviors in mice (83)

Inhibition of the hyaluronidase enzyme in snake bite venom, reduction in tissue damage and increased survival time (84)


 

turmeric


Dosage


Based upon the wide body of evidence, doses of 500-8,000mg of turmeric per day have been used in human studies, however standard extracts are typically used in lower amounts (approximately the 250-2,000mg range).

Periods of 3-4 months are well established to be suitable for turmeric/curcumin usage!


Take Home Message

The benefits of turmeric (and its main active ingredient, curcumin) are vast!

The antioxidant and anti-inflammatory effects seen in therapeutic and laboratory studies indicate to us that the usage of this spice throughout history is based upon very real molecular mechanisms.

As such, it behooves us to consider increasing our intake of turmeric to ensure we take advantage of its effects. Go on, spice up your life!

Our articles should be used for informational and educational purposes only and are not intended to be taken as medical advice. If you’re concerned, consult a health professional before taking dietary supplements or introducing any major changes to your diet.


  1. Krishnaswamy, Kamala. “Traditional Indian spices and their health significance.” Asia Pacific journal of clinical nutrition 17, no. S1 (2008): 265-268.
  2. Govindarajan VS. Turmeric–chemistry, technology, and quality.Crit Rev Food Sci Nutr. 1980;12:199-301
  3. I. Chattopadhyay, K. Biswas, U. Bandyopadhyay, and R. K. Banerjee, Turmeric and curcumin: Biological actions and medicinal applications. Curr Sci 87, 44–50 (2004)
  4. H. Ahsan, N. Parveen, N. U. Khan, and S. M. Hadi, Pro-oxidant, anti-oxidant and cleavage activities on DNA of curcumin and its derivatives demethoxycurcumin and bisdemethoxycurcumin. Chem Biol Interact 121, 161–175 (1999).
  5. N. Sreejayan and M. N. Rao, Free radical scavenging activity of curcuminoids. Arzneimittelforschung 46, 169–171 (1996).
  6. J. A. Duke, CRC Handbook of Medicinal Spices, 137–144 (2002). CRC Press C. Niederau and E. Gopfert, [The effect of chelidonium- and turmeric root extract on upper abdominal pain due to functional disorders of the biliary system. Results from a placebo-controlled double-blind study]. Med Klin (Munich) 94, 425–430 (1999).(No authors listed). Curcuma longa (turmeric). Monograph. Altern Med Rev 6(Suppl), S62–S66 (2001). http://www.ncbi.nlm.nih.gov/pubmed/11591174
  7. A. Tawatsin, S. D. Wratten, R. R. Scott, U. Thavara, and Y. Techadamrongsin, repellency of volatile oils from plants against three mosquito vectors. J Vector Ecol 26, 76–82 (2001).
  8. G. Bouvier, M. Hergenhahn, A. Polack, G.W. Bornkamm, and H. Bartsch, Validation of two test systems for detecting tumor promoters and EBV inducers: comparative responses of several agents in DR-CAT Raji cells and in human granulocytes. Carcinogenesis 14, 1573–1578 (1993).
  9. A. P. Saikia, V. K. Ryakala, P. Sharma, P. Goswami. and U. Bora, Ethnobotany of medicinal plants used by Assamese people for various skin ailments and cosmetics. J Ethnopharmacol 106, 149–157 (2006)
  10. S. Zheng and A. Chen, Activation of PPAR_ is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 384, 149–157 (2004).
  11. A. Chen and J. Xu, Activation of PPAR_ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 288, G447–G456 (2005).
  12. A. S. Jaiswal, B. P. Marlow, N. Gupta, and S. Narayan, Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)- induced growth arrest and apoptosis in colon cancer cells. Oncogene 21, 8414–8427 (2002).
  13. M. K. Bae, S. H. Kim, J.W. Jeong, Y. M. Lee, H. S. Kim, S. R. Kim, I. Yun, S. K. Bae, and K.W. Kim, Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep 15, 1557–1562 (2006).
  14. H. Choi,Y. S. Chun, S.W. Kim, M. S. Kim, and J.W. Park, Curcumin inhibits hypoxiainducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: A mechanism of tumor growth inhibition. Mol Pharmacol 70(5), 1664–1671 (2006).
  15. C. Natarajan and J. J. Bright, Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168, 6506–6513 (2002).
  16. M. Tomita, B. J. Holman, C. P. Santoro, and T. J. Santoro, Astrocyte production o the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription. J Neuroinflammation 2, 8 (2005).
  17. S. Zheng and A. Chen, Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor.AmJ Physiol Gastrointest Liver Physiol 290, G883–G893 (2006).
  18. A. Masamune, N. Suzuki, K. Kikuta, M. Satoh, K. Satoh, and T. Shimosegawa, Curcumin blocks activation of pancreatic stellate cells. J Cell Biochem 97, 1080–1093 (2006).
  19. X. Yang, D. P. Thomas, X. Zhang, B. W. Culver, B. M. Alexander, W. J. Murdoch, M. N. Rao, D. A. Tulis, J. Ren, and N. Sreejayan, Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol 26, 85–90 (2006).
  20. R. L. Hong, W. H. Spohn, and M. C. Hung, Curcumin inhibits tyrosine kinase activity of p185neu and also depletes p185neu. Clin Cancer Res 5, 1884–1891 (1999).
  21. T. Dorai, N. Gehani, and A. Katz, Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. Mol Urol 4, 1–6 (2000).
  22. Satoskar, R.R., Shah, S.J. and Shenoy, S.G., 1986. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. International journal of clinical pharmacology, therapy, and toxicology, 24(12), p.651.
  23. Takada, Y., Bhardwaj, A., Potdar, P. and Aggarwal, B.B., 2004. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene, 23(57), pp.9247-9258.
  24. R. G. Tunstall, R. A. Sharma, S. Perkins, S. Sale, R. Singh, P. B. Farmer,W. P. Steward, and A. J. Gescher, Cyclooxygenase-2 expression and oxidativeDNAadducts in murine intestinal adenomas: Modification by dietary curcumin and implications for clinical trials. Eur J Cancer 42, 415–421 (2006).
  25. J. Hong, M. Bose, J. Ju, J. H. Ryu, X. Chen, S. Sang, M. J. Lee, and C. S. Yang, Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25, 1671–1679 (2004).
  26. D. L. Flynn, M. F. Rafferty, and A. M. Boctor, Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins Leukot Med 22, 357–360 (1986).
  27. J. Hong, M. Bose, J. Ju, J. H. Ryu, X. Chen, S. Sang, M. J. Lee, and C. S. Yang, Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis 25, 1671–1679 (2004).
  28. N. S. Prasad, R. Raghavendra, B. R. Lokesh, and K. A. Naidu, Spice phenolics inhibit humanPMNL5-lipoxygenase. Prostaglandins Leukot Essent Fatty Acids 70, 521–528 (2004).
  29.  M. M. Chan, Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 49, 1551–1556 (1995).
  30. M. K. Jang, D. H. Sohn, and J. H. Ryu,Acurcuminoid and sesquiterpenes as inhibitors of macrophage TNF-alpha release from Curcuma zedoaria. Planta Med 67, 550–552 (2001).
  31. H. Matsuda, S. Tewtrakul, T. Morikawa, A. Nakamura, and M. Yoshikawa, Antiallergic principles from Thai zedoary: structural requirements of curcuminoids for inhibition of degranulation and effect on the release of TNF-alpha and IL-4 in RBL-2H3 cells. Bioorg Med Chem 12, 5891–5898 (2004).
  32. A. Gulcubuk, K. Altunatmaz, K. Sonmez, D. Haktanir-Yatkin, H. Uzun, A. Gurel and S. Aydin, Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med A Physiol Pathol Clin Med 53, 49–54 (2006).
  33. C. Natarajan and J. J. Bright, Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. J Immunol 168, 6506–6513 (2002).
  34. M. Tomita, B. J. Holman, C. P. Santoro, and T. J. Santoro, Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription. J Neuroinflammation 2, 8 (2005).
  35. S. Singh and B. B. Aggarwal, Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270, 24,995–25,000 (1995).
  36. A. Bierhaus,Y. Zhang, P. Quehenberger, T. Luther, M. Haase, M. Muller, N. Mackman, R. Ziegler, and P. P. Nawroth, The dietary pigment curcumin reduces endothelial tissue factor gene expression by inhibiting binding of AP-1 to the DNA and activation of NF-kappa B. Thromb Haemost 77, 772–782 (1997).
  37. A. Munzenmaier, C. Lange, E. Glocker, A. Covacci, A. Moran, S. Bereswill, P. A. Baeuerle, M. Kist, and H. L. Pahl, A secreted/shed product of Helicobacter pylori activates transcription factor nuclear factor-kappa B. J Immunol 159, 6140–6147 (1997).
  38. U. R. Pendurthi, J. T.Williams, and L.V. Rao, Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin. Suppression of activation of transcription factors Egr-1, AP-1, and NF-kappa B. Arterioscler Thromb Vasc Biol 17, 3406–3413 (1997).
  39. Y. X. Xu, K. R. Pindolia, N. Janakiraman, R. A. Chapman, and S. C. Gautam, Curcumin inhibits IL1 alpha and TNF-alpha induction of AP-1 and NF-kBDNA-binding activity in bone marrow stromal cells. Hematopathol Mol Hematol 11, 49–62 (1997).
  40. Onoda, M. and Inano, H., 2000. Effect of curcumin on the production of nitric oxide by cultured rat mammary gland. Nitric Oxide, 4(5), pp.505-515.
  41. K. Okada, C. Wangpoengtrakul, T. Tanaka, S. Toyokuni, K. Uchida, and T. Osawa, Curcumin and especially tetrahydrocurcumin ameliorate oxidative stress-induced renal injury in mice. J Nutr 131, 2090–2095 (2001)
  42. Y. Nakamura, Y. Ohto, A. Murakami, T. Osawa, and H. Ohigashi, Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promoter-induced reactive oxygen species generation in leukocytes in vitro and in vivo. Jpn J Cancer Res 89, 361–370 (1998)
  43. T. T. Phan, P. See, S. T. Lee, and S. Y. Chan, Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing. J Trauma 51, 927–931 (2001).
  44. S. C. Sahu and M. C.Washington, Effect of ascorbic acid and curcumin on quercetininduced nuclear DNA damage, lipid peroxidation and protein degradation. Cancer Lett 63, 237–241 (1992).
  45. I. A. Donatus, Sardjoko, and N. P. Vermeulen, Cytotoxic and cytoprotective activities of curcumin. Effects on paracetamol-induced cytotoxicity, lipid peroxidation and glutathione depletion in rat hepatocytes. Biochem Pharmacol 39, 1869–1875 (1990).
  46. S. C. Sahu and M. C.Washington, Effect of ascorbic acid and curcumin on quercetininduced nuclear DNA damage, lipid peroxidation and protein degradation. Cancer Lett 63, 237–241 (1992).
  47. K. K. Soudamini, M. C. Unnikrishnan, K. B. Soni, and R. Kuttan, Inhibition of lipid peroxidation and cholesterol levels in mice by curcumin. Indian J Physiol Pharmacol 36, 239–243 (1992).
  48. J. L. Quiles, C. Aguilera, M. D. Mesa, M. C. Ramirez-Tortosa, L. Baro, and A. Gil, An ethanolic-aqueous extract of Curcuma longa decreases the susceptibility of liver microsomes and mitochondria to lipid peroxidation in atherosclerotic rabbits. Biofactors 8, 51–57 (1998).
  49. L. M. Antunes, J. D. Darin, and L. Bianchi Nde, Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats. Pharmacol Res 43, 145–150 (2001).
  50. A. Singh, S. P. Singh, and R. Bamezai, Postnatal modulation of hepatic biotransformation system enzymes via translactational exposure of F1 mouse pups to turmeric and curcumin. Cancer Lett 96, 87–93 (1995).
  51. S. Oetari, M. Sudibyo, J. N. Commandeur, R. Samhoedi, and N. P. Vermeulen, Effects of curcumin on cytochrome P450 and glutathione S–transferase activities in rat liver. Biochem Pharmacol 51, 39–45 (1996).
  52. A. Singh, S. P. Singh, and R. Bamezai, Effect of arecoline on the curcumin-modulated hepatic biotransformation system enzymes in lactating mice and translactationally exposed F1 pups. Nutr Cancer 25, 101–110 (1996).
  53. M. L. van Iersel, J. P. Ploemen, M. Lo Bello, G. Federici, and P. J. van Bladeren, Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact 108, 67–78 (1997).
  54. M. Iqbal, S. D. Sharma, Y. Okazaki, M. Fujisawa, and S. Okada, Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol Toxicol 92, 33–38 (2003).
  55. M. K. Unnikrishnan and M. N. Rao, Curcumin inhibits nitrite-induced methemoglobin formation. FEBS Lett 301, 195–196 (1992).
  56. Akram, M., Uddin, S., Ahmed, A., Usmanghani, K., Hannan, A., Mohiuddin, E. and Asif, M., 2010. Curcuma longa and curcumin: a review article. Rom J Biol Plant Biol, 55(2), pp.65-70.
  57. R. R. Satoskar, S. J. Shah, and S. G. Shenoy, Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol 24, 651–654 (1986).
  58. T. K. Biswas and B. Mukherjee, Plant medicines of Indian origin for wound healing activity: A review. Int J Low Extrem Wounds 2, 25–39 (2003).
  59. G. S. Sidhu, A. K. Singh, D. Thaloor, K. K. Banaudha, G. K. Patnaik, R. C. Srimal, and R. K. Maheshwari, Enhancement of wound healing by curcumin in animals. Wound Repair Regen 6, 167–177 (1998).
  60. G. S. Sidhu, H. Mani, J. P. Gaddipati, A. K. Singh, P. Seth, K. K. Banaudha, G. K. Patnaik, and R. K. Maheshwari, Curcumin enhances wound healing in streptozotocin induced diabetic rats and genetically diabetic mice. Wound Repair Regen 7, 362–374 (1999).
  61. T. T. Phan, P. See, S. T. Lee, and S. Y. Chan, Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing. J Trauma 51, 927–931 (2001).
  62. S. D. Deodhar, R. Sethi, and R. C. Srimal, Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J Med Res 71, 632–634.
  63. A. Liacini, J. Sylvester, W. Q. Li, and M. Zafarullah, Inhibition of interleukin-1- stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol 21, 251–262 (2002).
  64. A. Liacini, J. Sylvester,W. Q. Li,W. Huang, F. Dehnade,M.Ahmad, andM.Zafarullah, Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated byMAPkinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res 288, 208–217 (2003).
  65. J. Sylvester, A. Liacini,W. Q. Li, and M. Zafarullah, Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell Signal 16, 469–476 (2004) Arthritis,105,338–341
  66. B. Joe, U. J. Rao, and B. R. Lokesh, Presence of an acidic glycoprotein in the serum of arthritic rats: modulation by capsaicin and curcumin. Mol Cell Biochem 169, 125–134 (1997).
  67. P. A. Cerutti, Prooxidant states and tumor promotion. Science 227, 375–381 (1985).
  68. R. Kuttan, P. C. Sudheeran, and C. D. Josph, Turmeric and curcumin as topical agents in cancer therapy. Tumori 73(1), 29–31 (1987)
  69. S. Aggarwal, Y. Takada, S. Singh, J. N. Myers, and B. B. Aggarwal, Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer 111, 679–692 (2004).
  70. G. Radhakrishna Pillai, A. S. Srivastava, T. I. Hassanein, D. P. Chauhan, and E. Carrier, Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett 208, 163–170 (2004).
  71. L. Li, B. B. Aggarwal, S. Shishodia, J. Abbruzzese, and R. Kurzrock, Nuclear factorkappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer 101, 2351–2362 (2004)
  72. M. Shi, Q. Cai, L. Yao, Y. Mao, Y. Ming, and G. Ouyang, Antiproliferation and apoptosis induced by curcumin in human ovarian cancer cells. Cell Biol Int 30, 221– 226 (2006).
  73. C. Ramachandran, S. Rodriguez, R. Ramachandran, P. K. Raveendran Nair, H. Fonseca, Z. Khatib, E. Escalon, and S. J. Melnick, Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines. Anticancer Res 25, 3293–3302 (2005).
  74. A. Gulcubuk, K. Altunatmaz, K. Sonmez, D. Haktanir-Yatkin, H. Uzun, A. Gurel and S. Aydin, Effects of curcumin on tumour necrosis factor-alpha and interleukin-6 in the late phase of experimental acute pancreatitis. J Vet Med A Physiol Pathol Clin Med 53, 49–54 (2006).
  75. P. R. Holt, S. Katz, and R. Kirshoff, Curcumin therapy in inflammatory bowel disease: A pilot study. Dig Dis Sci 50, 2191–2193(2005).
  76. K. Sugimoto, H. Hanai, K. Tozawa, T. Aoshi, M. Uchijima, T. Nagata, and Y. Koide, Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123, 1912–1922 (2002).
  77. D. C. Kim, S. H. Kim, B. H. Choi, N. I. Baek, D. Kim, M. J. Kim, and K. T. Kim, Curcuma longa extract protects against gastric ulcers by blocking H2 histamine receptors. Biol Pharm Bull 28, 2220–2224 (2005).
  78. O. S. Baek, O. H. Kang, Y. A. Choi, S. C. Choi, T. H. Kim, Y. H. Nah, D. Y. Kwon, Y. K. Kim, Y. H. Kim, K. H. Bae, J. P. Lim, and Y. M. Lee, Curcumin inhibits protease-activated receptor-2 and -4-mediated mast cell activation. Clin Chim Acta 338, 135–141 (2003).
  79. M. C. Heng, M. K. Song, J. Harker, and M. K. Heng, Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters. Br J Dermatol 143(5), 937–949 (2000)
  80. C. J. Li, L. J. Zhang, B. J. Dezube, C. S. Crumpacker, and A. B. Pardee, Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA 90, 1839–1842 (1993).
  81. Y. Xu, B. S. Ku, H. Y. Yao, Y. H. Lin, X. Ma, Y. H. Zhang, and X. J. Li, The effects of curcumin on depressive-like behaviors in mice. Eur J Pharmacol 518, 40–46 (2005).
  82. K. S. Girish and K. Kemparaju, Inhibition of Naja naja venom hyaluronidase by plantderived bioactive components and polysaccharides. Biochemistry (Mosc) 70, 948–952 (2005).
  83. Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., Ko, J. Y., Lin, J. T., Lin, B. R., Wu, M. S., Yu, H. S., Jee, S. H., Chen, G. S., Chen, T. M., Chen, C. A., Lai, M. K., Pu, Y. S., Pan, M. H., Wang, Y. J., Tsai, C. C., and Hsieh, C. Y., 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high–risk or pre–malignant lesions. Anticancer Res 21(4B), 2895–2900.
  84. C. D. Lao, M. T. t. Ruffin, D. Normolle, D. D. Heath, S. I. Murray, J. M. Bailey, M. E. Boggs, J. Crowell, C. L. Rock, and D. E. Brenner, Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6, 10 (2006).


Myprotein

Myprotein

Writer and expert


Rewarding our readers – check out our best sellers now Be quick, shop now!